Moleculin Biotech Inc
moleculin.comWhat Do They Do?
Develops drug candidates for hard-to-treat cancers and viruses, including Annamycin for people with relapsed or refractory acute myeloid leukemia.
10-K for FY2025, filed Mar 18, 2026We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name…View ↗
We have two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by…View ↗
a) Annamycin is what we believe to be a “next-generation” anthracycline (one of the most widely used classes of chemotherapy), designed to…View ↗
b) Our WP1066 Portfolio includes WP1066, WP1193 and WP1220, three of several Immune/Transcription Modulators in the portfolio designed to…View ↗
c) Our WP1122 Portfolio contains compounds (including WP1122, WP1096, and WP1097) designed to exploit the potential uses of inhibitors of…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 18, 2026
How Are They Changing?
Narrower development focus
The older report names separate Annamycin programs for lung-metastatic sarcoma and leukemia, alongside delivery work for another portfolio. The latest says Moleculin mainly focuses on Annamycin and advances other candidates through investigator-led research as resources allow.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 18, 2026We are focused on internally funded (“internally” and “externally” funded trials are defined in the Funding Strategy section below)…View ↗
1) Annamycin for the treatment of Soft Tissue Sarcoma metastasized to the lungs (STS lung metastases or STS lung mets) 2) Annamycin in…View ↗
3) Developing a better delivery mechanism for WP1066 to further support current and possibly future externally funded oncology clinical…View ↗
One of our core management beliefs is that anthracyclines represent one of the most important treatments available for AML and Advanced…View ↗
Internally funded – In combination with Cytarabine (also known as Ara-C, the combination with Annamycin of which is referred to as AnnAraC)…View ↗
Externally funded – Advancing beyond our initial Phase 1B/2 internally funded trial for the treatment of STS metastasized to the lungs.View ↗
Loading...
